Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
About the newest pharmacotherapy mechanisms of action under clinical investigation in the second-line setting, Heme Today asked Dr. Broome and Dr. Cuker which ones have piqued ITP clinicians’ interest. Two drug classes mentioned by both experts in their written remarks were B-cell-activating factor (BAFF) inhibitors and anti-CD38 monoclonal antibodies.
On what is gene therapy’s greatest significance for SCD management, all three experts in their written responses to Heme Today explained that it offers patients a dramatically effective, potentially curative, clinical option.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
